Founded in 2010 by Dr Olivier Loget DVM, ERT CapEval Pharma provides pharmaceutical consultancy services in early pre-clinical to clinical development.
We provide our services all around the world to start-up, big and middle size pharma developing NCE's and NBE's
We would be very glad to share our network and expertise with you.
A CNS startup was not able to expose the selected non-rodent, because dogs vomited
CapEval has been able to show that the dog was not the appropriate species and the non-clinical development was successfully completed with minipigs (without vomiting).
During a Due Diligence for a CNS compound supported by CapEval, positive hERG data where identified
CapEval has been able to implement a derisking cardiac strategy and to use this for negotiating the deal.
A startup had muscle effects in a rat study
CapEval has been able to implement a kinetic follow-up of the findings and to show that this was not relevant to humans.
A startup was about to stop a CNS project because of genotox effects during an in vivo MNT with a metabolite
CapEval has been able to prove that the route of exposure was not appropriate and to derisk the project by changing the route for better mimicking exposure to the metabolite.
CapEval Pharma
218 Av. Marie Curie, 74160 Archamps France